Skip to content

Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions

Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05730855
Enrollment
45
Registered
2023-02-16
Start date
2022-11-01
Completion date
2023-01-23
Last updated
2023-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukoplakia, Oral, Oral Lichen Planus, Potentially Malignant Lesions

Keywords

lncRNA DQ786243, saliva, oral potentially malignant lesions, miRNA146a

Brief summary

The aim of this study is to evaluate salivary expression of lncRNA DQ786243 as a potential marker for diagnosis of oral potentially malignant lesions compared to normal controls and its effect on salivary expression of miRNA146a.

Interventions

DIAGNOSTIC_TESTReal-time Polymerase Chain Reaction technique

Real-time Polymerase Chain Reaction technique

Sponsors

Fayoum University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* participants will be divided into 3 groups: Group I: patients suffering from oral lichen planus Group II: patients suffering from leukoplakia Group III: healthy subjects who are systemically free, non-smokers, and not suffering from any oral mucosal lesions.

Exclusion criteria

* Subjects taking any drugs inducing any changes that could affect the salivary flow. * Pregnant females. * Subjects have any allergies, infectious diseases or active dental abscesses during one month before saliva sampling. * Patients receiving any drugs related to the oral lesions in the past 6 month prior to sample collection.

Design outcomes

Primary

MeasureTime frame
salivary expression of lncDQ786243 in OLP, Leukoplakia, control2 months

Secondary

MeasureTime frame
salivary expression of miRNA146a in OLP, Leukoplakia, control2 months

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026